Susquehanna International Group’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $477K | Sell |
21,100
-37,600
| -64% | -$836K | ﹤0.01% | 9802 |
|
|
2025
Q4 | $1.52M | Buy |
58,700
+3,400
| +6% | +$80.8K | ﹤0.01% | 6211 |
|
|
2025
Q3 | $1.43M | Buy |
55,300
+39,800
| +257% | +$978K | ﹤0.01% | 6513 |
|
|
2025
Q2 | $370K | Buy |
15,500
+2,100
| +16% | +$52.9K | ﹤0.01% | 9869 |
|
|
2025
Q1 | $333K | Sell |
13,400
-83,300
| -86% | -$1.99M | ﹤0.01% | 9842 |
|
|
2024
Q4 | $1.82M | Buy |
96,700
+8,000
| +9% | +$140K | ﹤0.01% | 5532 |
|
|
2024
Q3 | $1.33M | Buy |
88,700
+33,000
| +59% | +$564K | ﹤0.01% | 6176 |
|
|
2024
Q2 | $1.59M | Buy |
+55,700
| New | +$1.59M | ﹤0.01% | 5541 |
|
|
2024
Q1 | – | Sell |
-146,900
| Closed | -$4.96M | – | 13040 |
|
|
2023
Q4 | $4.96M | Buy |
146,900
+111,600
| +316% | +$3.27M | ﹤0.01% | 3712 |
|
|
2023
Q3 | $1.08M | Sell |
35,300
-28,900
| -45% | -$1.04M | ﹤0.01% | 6452 |
|
|
2023
Q2 | $2.57M | Buy |
64,200
+2,900
| +5% | +$120K | ﹤0.01% | 4641 |
|
|
2023
Q1 | $2.5M | Buy |
+61,300
| New | +$2.44M | ﹤0.01% | 4686 |
|
|
2022
Q4 | – | Sell |
-22,400
| Closed | -$1.19M | – | 13347 |
|
|
2022
Q3 | $1.19M | Buy |
22,400
+10,000
| +81% | +$556K | ﹤0.01% | 6182 |
|
|
2022
Q2 | $723K | Sell |
12,400
-1,000
| -7% | -$65.5K | ﹤0.01% | 7339 |
|
|
2022
Q1 | $1.02M | Buy |
13,400
+4,400
| +49% | +$293K | ﹤0.01% | 7055 |
|
|
2021
Q4 | $542K | Sell |
9,000
-10,700
| -54% | -$590K | ﹤0.01% | 8969 |
|
|
2021
Q3 | $1.1M | Buy |
19,700
+6,300
| +47% | +$363K | ﹤0.01% | 7297 |
|
|
2021
Q2 | $813K | Sell |
13,400
-14,600
| -52% | -$924K | ﹤0.01% | 8320 |
|
|
2021
Q1 | $1.96M | Sell |
28,000
-8,600
| -23% | -$614K | ﹤0.01% | 5973 |
|
|
2020
Q4 | $2.19M | Buy |
36,600
+9,300
| +34% | +$545K | ﹤0.01% | 4907 |
|
|
2020
Q3 | $1.64M | Sell |
27,300
-43,300
| -61% | -$2.52M | ﹤0.01% | 4993 |
|
|
2020
Q2 | $3.7M | Buy |
70,600
+11,200
| +19% | +$468K | ﹤0.01% | 3452 |
|
|
2020
Q1 | $1.99M | Sell |
59,400
-10,400
| -15% | -$432K | ﹤0.01% | 3970 |
|
|
2019
Q4 | $3.16M | Buy |
69,800
+22,700
| +48% | +$964K | ﹤0.01% | 3621 |
|
|
2019
Q3 | $1.79M | Sell |
47,100
-49,200
| -51% | -$1.96M | ﹤0.01% | 4430 |
|
|
2019
Q2 | $4.19M | Sell |
96,300
-68,300
| -41% | -$2.9M | ﹤0.01% | 2957 |
|
|
2019
Q1 | $6.26M | Sell |
164,600
-33,600
| -17% | -$1.31M | ﹤0.01% | 2204 |
|
|
2018
Q4 | $8.53M | Buy |
198,200
+57,700
| +41% | +$2.69M | ﹤0.01% | 1760 |
|
|
2018
Q3 | $6.91M | Buy |
140,500
+12,600
| +10% | +$545K | ﹤0.01% | 2306 |
|
|
2018
Q2 | $4.1M | Buy |
127,900
+9,400
| +8% | +$325K | ﹤0.01% | 2972 |
|
|
2018
Q1 | $3.69M | Sell |
118,500
-57,500
| -33% | -$2.05M | ﹤0.01% | 2933 |
|
|
2017
Q4 | $8.03M | Buy |
176,000
+111,600
| +173% | +$4.42M | ﹤0.01% | 2026 |
|
|
2017
Q3 | $2.42M | Sell |
64,400
-46,300
| -42% | -$1.86M | ﹤0.01% | 3567 |
|
|
2017
Q2 | $5.28M | Sell |
110,700
-19,700
| -15% | -$914K | ﹤0.01% | 2344 |
|
|
2017
Q1 | $5.95M | Sell |
130,400
-56,800
| -30% | -$2.46M | ﹤0.01% | 2172 |
|
|
2016
Q4 | $6.05M | Buy |
187,200
+2,300
| +1% | +$76.8K | ﹤0.01% | 2133 |
|
|
2016
Q3 | $6.33M | Buy |
184,900
+126,900
| +219% | +$4.97M | ﹤0.01% | 1976 |
|
|
2016
Q2 | $1.96M | Sell |
58,000
-205,000
| -78% | -$10.1M | ﹤0.01% | 3607 |
|
|
2016
Q1 | $13.9M | Buy |
263,000
+60,400
| +30% | +$3.53M | 0.01% | 1263 |
|
|
2015
Q4 | $15.6M | Buy |
202,600
+56,200
| +38% | +$3.18M | 0.01% | 1350 |
|
|
2015
Q3 | $6.02M | Sell |
146,400
-87,100
| -37% | -$5.33M | ﹤0.01% | 2418 |
|
|
2015
Q2 | $16.5M | Buy |
233,500
+47,300
| +25% | +$3.73M | 0.01% | 1489 |
|
|
2015
Q1 | $16.5M | Buy |
186,200
+68,600
| +58% | +$6.96M | 0.01% | 1395 |
|
|
2014
Q4 | $10.4M | Buy |
117,600
+47,900
| +69% | +$4.53M | ﹤0.01% | 1994 |
|
|
2014
Q3 | $6.75M | Buy |
69,700
+43,000
| +161% | +$4.18M | ﹤0.01% | 2596 |
|
|
2014
Q2 | $2.45M | Sell |
26,700
-29,900
| -53% | -$2.28M | ﹤0.01% | 4257 |
|
|
2014
Q1 | $3.96M | Sell |
56,600
-44,800
| -44% | -$3.05M | ﹤0.01% | 3222 |
|
|
2013
Q4 | $5.83M | Buy |
101,400
+64,200
| +173% | +$3.38M | ﹤0.01% | 2730 |
|
|
2013
Q3 | $1.79M | Buy |
37,200
+23,400
| +170% | +$853K | ﹤0.01% | 4284 |
|
|
2013
Q2 | $400K | Buy |
+13,800
| New | +$399K | ﹤0.01% | 6372 |
|
Other funds holding PCRX
DPCM
VPM
VCM
Susquehanna International Group's PCRX Position: Q1 2026 in Review
Susquehanna International Group increased its Pacira BioSciences (PCRX) stake by 30% in Q1 2026, buying an estimated $182K and bringing the position to 35,483 shares worth $802K. The position accounts for ﹤0.01% of the portfolio, ranked #8467.
Susquehanna International Group first reported a position in PCRX in Q2 2013 and has held it in 42 quarters since. The position peaked at $8.55M in Q4 2016. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.
- Susquehanna International Group held 35,483 shares of Pacira BioSciences worth $802K as of Q1 2026.
- Susquehanna International Group bought 8,189 Pacira BioSciences shares in Q1 2026, an estimated $182K.
- Pacira BioSciences made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #8467 holding.
- Susquehanna International Group first reported a position in Pacira BioSciences in Q2 2013 and has held it in 42 quarters since.
- Susquehanna International Group's Pacira BioSciences position peaked at $8.55M in Q4 2016.
- 241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.